特发性肺纤维化患者住院资源使用与费用:IPF-PRO登记研究
基于美国IPF-PRO前瞻性登记研究中300例新诊断或确诊IPF患者,随访12个月发现平均每人0.42次住院、0.11次急诊就诊、0.08次ICU入住;6个月和12个月住院概率分别为18%和30%,住院和ICU年均费用分别为13975美元和10098美元。
要点
- IPF患者12个月内平均住院0.42次、ICU入住0.08次,住院概率6个月18%、12个月30%。
- 住院和ICU年均费用分别为13975美元和10098美元,经济负担显著。
- FVC<50%预计值或DLCO<30%预计值者住院概率最高。
核心结论
- IPF患者需要住院治疗时产生显著经济负担。
研究设计与样本
- 基于美国IPF-PRO前瞻性登记研究,纳入2014年6月5日至2016年4月12日入组的300例新诊断或确诊IPF患者。
主要发现
- 随访12个月内平均每人急诊就诊0.11次、住院0.42次、ICU入住0.08次、住院日2.18天、ICU日0.45天。
- 6个月和12个月住院概率分别为18%和30%。
- FVC<50%预计值或DLCO<30%预计值者住院概率最高。
- 住院和ICU年均费用分别为13975美元(95%CI 8482-20918)和10098美元(95%CI 4732-16662)。
临床怎么用
- 对IPF患者,尤其FVC<50%预计值或DLCO<30%预计值者,应关注住院风险及相应经济负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a rare and serious condition that is associated with high health-care resource use. The goal of this study was to estimate hospital-related resource use and costs by using a national, prospective registry of patients who were diagnosed with IPF or who had their diagnosis confirmed at the enrolling center in the past 6 months in the United States. METHODS: Participants enrolled between June 5, 2014, and April 12, 2016, in the ongoing Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry were included (N = 300). Time to first hospitalization was analyzed by using Kaplan-Meier methods. Annualized costs were estimated for hospitalizations, ICU admissions, and ED visits. RESULTS: At enrollment, most participants were male (75%), white (95%), commercially insured (64%), smokers (68%), had an FVC between 50% and 80% predicted (66%), and received antifibrotic drugs (55%). During the first 12 months of follow-up, participants averaged 0.11 ED visit, 0.42 hospitalization, 0.08 ICU admission, 2.18 hospital days, and 0.45 ICU day. Probability of hospitalization was 18% and 30% at 6 and 12 months, respectively, and was highest for those with FVC < 50% predicted/diffusing lung capacity for carbon monoxide < 30% predicted. Mean annual costs (95% CI) for ICU admission and inpatient care were $10,098 ($4,732-$16,662) and $13,975 ($8,482-$20,918), respectively, per patient. CONCLUSIONS: IPF is associated with a substantial economic burden incurred by patients requiring hospital care. Future research in IPF should focus on improving clinical outcomes while reducing cost of care in hospitals. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01915511; URL: www.clinicaltrials.gov.
引用
- Fan Y, Bender SD, Conoscenti CS, et al. Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Chest. 2020. PMID: 32004554. doi:10.1016/j.chest.2019.12.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。